Actually its 25 years from the date of marketing approval.
Makes for a interesting NPV given the TAM.
Sensitivity analysis for distribution deals will need to include re-occurring revenue from booster shots (circa 6 to 12 months post treatment).
Even at a static 10% y-on-y penetration rate of market means will compound of revenue growth (assuming it defers TKR for 5-10 years)
research reports and media, page-2201
-
- There are more pages in this discussion • 2,248 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
0.020(9.76%) |
Mkt cap ! $76.98M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 22.5¢ | 21.0¢ | $101.7K | 471.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 37200 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.5¢ | 91011 | 4 |
View Market Depth
| Last trade - 12.27pm 04/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |